Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer
This translational study suggests that pyrotinib combined with oxaliplatin may serve as a promising strategy for patients with EGFR-high copy number gastric cancer and highlighted the discovery of this previously unknown EGFR/ GRP78 signaling axis, which provides the molecular basis and the rationale to target EGFR.
Authors
- Nana Hu
- Nan Dai
- Jing Yang (ORCID: https://orcid.org/0000-0003-2733-8629)
- Xiuyong Liao
- Yuancheng Zhao
- Mengxia Li (ORCID: https://orcid.org/0000-0003-4443-740X)
- Xiaoyan Dai (ORCID: https://orcid.org/0000-0001-5695-6384)
- Xudong Wang (ORCID: https://orcid.org/0000-0003-1596-9191)
- Dong Wang (ORCID: https://orcid.org/0000-0001-5579-8572)
- Zheng Liu (ORCID: https://orcid.org/0000-0002-1635-1556)
- Qian Chen (ORCID: https://orcid.org/0000-0002-1487-5479)
- Lingbo Bao
- Yue Hu (ORCID: https://orcid.org/0000-0002-1116-7303)
- Li Dong (ORCID: https://orcid.org/0000-0002-3625-1878)
- Jinlu Shan (ORCID: https://orcid.org/0009-0005-1669-9033)
- Zhenjie He (ORCID: https://orcid.org/0009-0008-8841-1707)
- Xueling Tong
- ChunXue Li
Institutions
- Army Medical University (CN)
- Daping Hospital (CN)
- Chengdu Military General Hospital (CN)
- Qianjiang Central Hospital (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1186/s13046-025-03485-6
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52